UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Recruitment of the Earliest Component of the Bacterial Flagellum to the Old Cell Division Pole by a Membrane-Associated Signal Recognition Particle Family GTP-Binding Protein

Journal of molecular biology, 2009-08, Vol.391 (4), p.679-690

2009

Link zum Volltext

Verfügbarkeit prüfen

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults

BMC cancer, 2023-04, Vol.23 (1), p.360-360, Article 360

2023

Link zum Volltext

Verfügbarkeit prüfen

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

Current oncology (Toronto), 2022-11, Vol.29 (11), p.8686-8692

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy

Current oncology (Toronto), 2023-05, Vol.30 (6), p.5299-5308

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimising Cancer Vaccine Design in Sarcoma

Cancers, 2018-12, Vol.11 (1), p.1

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach

PloS one, 2015-09, Vol.10 (9), p.e0139074-e0139074

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world

Cancer medicine (Malden, MA), 2022-01, Vol.11 (1), p.86-93

2022

Link zum Volltext

Verfügbarkeit prüfen

Cell Death and Mechanoprotection by Filamin A in Connective Tissues after Challenge by Applied Tensile Forces

The Journal of biological chemistry, 2002-06, Vol.277 (24), p.21998-22009

2002

Link zum Volltext

Verfügbarkeit prüfen

Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world

Journal of clinical oncology, 2022-10, Vol.40 (28_suppl), p.126-126

2022

Link zum Volltext

Verfügbarkeit prüfen

Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Clinical cancer research, 2021-01, Vol.27 (1), p.202-212

2021

Link zum Volltext

Verfügbarkeit prüfen

Overall survival benefits of advances in NSCLC systemic treatments: Younger versus older adults

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.93-93

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular testing in non-small cell lung cancer: a snapshot of The Royal Free London NHS Foundation Trust experience

Lung cancer (Amsterdam, Netherlands), 2021-06, Vol.156, p.S38

2021

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of crizotinib in patients with -positive nonsmall cell lung cancer

Therapeutic advances in respiratory disease, 2015-06, Vol.9

2015

Link zum Volltext

Verfügbarkeit prüfen

Confirmation of germline variants identified by tumor testing: A population-based study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e13021-e13021

2019

Link zum Volltext

Verfügbarkeit prüfen

Lung Cancer in Canada

Journal of thoracic oncology, 2019-07, Vol.14 (7), p.1128-1133

2019

Link zum Volltext

Verfügbarkeit prüfen

Olaratumab: a platelet-derived growth factor receptor-[alpha]-blocking antibody for the treatment of soft tissue sarcoma

Clinical pharmacology: advances and applications, 2017-01, Vol.9, p.159

2017

Link zum Volltext

Verfügbarkeit prüfen

An audit of the management of Staphylococcus aureus bloodstream infections over two years in a District General Hospital in the United Kingdom: Category: Clinical lesson

The Journal of infection, 2011-12, Vol.63 (6), p.e78-e78

2011

Link zum Volltext

Verfügbarkeit prüfen

An audit of the management of Staphylococcus aureus bloodstream infections over two years in a District General Hospital in the United Kingdom

The Journal of infection, 2011-12, Vol.63 (6), p.e78-e78

2011

Link zum Volltext

Verfügbarkeit prüfen

Intratumoral heterogeneity in programmed death‐ligand 1 immunoreactivity is associated with variation in non‐small cell lung carcinoma histotype

Histopathology, 2020-02, Vol.76 (3), p.394-403

2020

Link zum Volltext

Verfügbarkeit prüfen

Olaratumab for the treatment of soft-tissue sarcoma

Future oncology (London, England), 2017-10, Vol.13 (24), p.2151-2157

2017

Link zum Volltext

Verfügbarkeit prüfen

Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9080-9080

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1647: CAPTIV-8: A prospective trial of atezolizumab using a multivariate model incorporating whole genome and transcriptome analysis

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1647-1647

2021

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer

Therapeutic Advances in Respiratory Disease, 2015-06, Vol.9 (3), p.97-104

2015

Link zum Volltext

Verfügbarkeit prüfen

The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space

The Journal of molecular diagnostics : JMD, 2022-06, Vol.24 (6), p.609-618

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(37)
Buchkapitel
(3)

Sprache

Englisch
(40)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Recruitment of the Earliest Component of the Bacterial Flagellum to the Old Cell Division Pole by a Membrane-Associated Signal Recognition Particle Family GTP-Binding Protein

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy

Optimising Cancer Vaccine Design in Sarcoma

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world

Cell Death and Mechanoprotection by Filamin A in Connective Tissues after Challenge by Applied Tensile Forces

Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world

Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Overall survival benefits of advances in NSCLC systemic treatments: Younger versus older adults

Molecular testing in non-small cell lung cancer: a snapshot of The Royal Free London NHS Foundation Trust experience

The efficacy of crizotinib in patients with -positive nonsmall cell lung cancer

Confirmation of germline variants identified by tumor testing: A population-based study

Lung Cancer in Canada

Olaratumab: a platelet-derived growth factor receptor-[alpha]-blocking antibody for the treatment of soft tissue sarcoma

An audit of the management of Staphylococcus aureus bloodstream infections over two years in a District General Hospital in the United Kingdom: Category: Clinical lesson

An audit of the management of Staphylococcus aureus bloodstream infections over two years in a District General Hospital in the United Kingdom

Intratumoral heterogeneity in programmed death‐ligand 1 immunoreactivity is associated with variation in non‐small cell lung carcinoma histotype

International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant

Olaratumab for the treatment of soft-tissue sarcoma

Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes

Abstract 1647: CAPTIV-8: A prospective trial of atezolizumab using a multivariate model incorporating whole genome and transcriptome analysis

The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer

The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space

Suchergebnisse filtern